Syros Pharmaceuticals Inc (SYRS) ニュース

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

-- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...

Form 8-K - Current report

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of...